Hybrid Coronary Revascularization Trial- DCC

混合冠状动脉血运重建试验 - DCC

基本信息

项目摘要

 DESCRIPTION (provided by applicant): Summary/Abstract Hybrid coronary revascularization (HCR) is the intentional combination of minimally invasive surgical grafting of the left anterior descending artery (LAD) coronary artery using the left internal mammary artery (LIMA) with percutaneous coronary intervention (PCI) of non-LAD coronary stenosis. HCR procedures are being adopted by clinicians nationwide, in an effort to reduce morbidity, mortality, recovery time, repeat re-interventions, and the costs of revascularization for patients with multi-vessel coronary artery disease (CAD) involving the LAD and/or left main coronary arteries. To date, there has been no randomized controlled trial to establish whether HCR achieves these results, and increasing adoption of HCR is proceeding without a solid evidence base. The proposed trial is designed to fill this knowledge gap and provide an evidence base for clinical practice. We propose a pragmatic, large-scale clinical trial that evaluates the effectiveness and safety of HCR compared to multi-vessel PCI. The trial will enroll 2354 patients with multi-vessel CAD involving the LAD distribution and a clinical indication for revascularization, who are eligible for both HCR and multi-vessel PCI with drug eluting stents. The primary outcome will be occurrence of MACCE, defined as all-cause mortality, myocardial infarction, stroke, and repeat revascularization over a minimum of 5 year follow-up after randomization. A vanguard phase will be conducted over the first year of the trial to establish feasibility of enrollment and data completeness of centralized collection of MACCE events. The innovative design of the trial combines collection and adjudication of minimal trial-specific data with national registry data (STS and NCDR), resulting in a streamlined and very cost-effective trial. A previous NIH-funded observational study (RC1 HL100951-01, Principal Investigators, J. Puskas, D. Ascheim), informing the design of this trial, demonstrated that 10-15% of patients with CAD are anatomically eligible for HCR and confirmed that equipoise exists among cardiologists and surgeons to randomize such patients. To conduct this trial, we have assembled a Hybrid Trial Network of 49 selected clinical sites experienced in multi-vessel PCI, minimally invasive LIMA-LAD grafting, and HCR. Co-Investigators from cardiology and cardiac surgery have signed Letters of Collaboration from all sites. In the past two years the Hybrid Network sites have performed >6500 CABG procedures and approximately 15,000 multi-vessel PCI procedures for patients with suitable coronary anatomy, and, therefore, have a large volume of patients eligible for HCR. The results of the Hybrid Trial could fundamentally change management of patients with CAD, the number one cause of death in the United States. This trial, which will support numerous clinical centers across the country and the DCC and CCC, will provide evidence to guide and improve treatment decisions and optimize the utilization of health care resources for this growing patient population.
 描述(由申请人提供):总结/摘要混合冠状动脉血运重建术(HCR)是使用左乳内动脉(LIMA)对左前降支(LAD)冠状动脉进行微创手术移植与非LAD冠状动脉狭窄的经皮冠状动脉介入治疗(PCI)的有意组合。HCR程序正在全国范围内被临床医生采用,以减少发病率,死亡率,恢复时间, 多支冠状动脉患者的重复再介入和血运重建费用 涉及LAD和/或左主干冠状动脉的动脉疾病(CAD)。到目前为止,还没有随机对照试验来确定HCR是否达到这些结果,并且越来越多的HCR采用正在进行中,没有坚实的证据基础。拟议的试验旨在填补这一知识空白,并为临床实践提供证据基础。我们提出了一个实用的,大规模的临床试验,评价HCR的有效性和安全性相比,多血管PCI。该试验将入组2354例患有涉及LAD分布的多血管CAD和血运重建的临床适应症的患者,这些患者符合HCR 和多血管PCI与药物洗脱支架。主要结局将是随机化后至少5年随访期间发生的MACCE,定义为全因死亡、心肌梗死、卒中和重复血运重建。将在试验的第一年进行先锋阶段,以确定入组的可行性和集中收集MACCE事件的数据完整性。该试验的创新设计将最少试验特定数据的收集和裁定与国家登记数据(STS和NCDR)相结合,从而实现了简化且极具成本效益的试验。先前由NIH资助的观察性研究(RC 1 HL 100951 -01,主要研究者,J. Puskas,D. Ascheim)的研究表明,10-15%的CAD患者在解剖学上符合HCR的条件,并证实心脏病专家和外科医生之间存在平衡,可以随机分配此类患者。为了进行这项试验,我们组建了一个混合试验网络,其中包括49家在多血管PCI、微创LIMA-LAD移植和HCR方面经验丰富的选定临床研究中心。来自心脏病学和心脏外科的合作研究者已签署了来自所有研究中心的合作函。在过去的两年中,混合网络站点已经为具有合适冠状动脉解剖结构的患者进行了超过6500例CABG手术和约15,000例多血管PCI手术,因此具有大量符合HCR条件的患者。混合试验的结果可能从根本上改变CAD患者的管理,CAD是美国的头号死亡原因。这项试验将支持全国各地的众多临床中心以及DCC和CCC,将提供证据来指导和改善治疗决策,并优化不断增长的患者群体的医疗保健资源利用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Emilia Bagiella其他文献

Emilia Bagiella的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Emilia Bagiella', 18)}}的其他基金

The Applied Statistics in Biological Systems (ASIBS) Short Course
生物系统应用统计学(ASIBS)短期课程
  • 批准号:
    8853106
  • 财政年份:
    2015
  • 资助金额:
    $ 166.44万
  • 项目类别:
The Applied Statistics in Biological Systems (ASIBS) Short Course
生物系统应用统计学(ASIBS)短期课程
  • 批准号:
    9059139
  • 财政年份:
    2015
  • 资助金额:
    $ 166.44万
  • 项目类别:
The Applied Statistics in Biological Systems (ASIBS) Short Course
生物系统应用统计学(ASIBS)短期课程
  • 批准号:
    9241407
  • 财政年份:
    2015
  • 资助金额:
    $ 166.44万
  • 项目类别:
Factors determining placebo response in drug-resistant focal epilepsy
决定耐药局灶性癫痫安慰剂反应的因素
  • 批准号:
    8670039
  • 财政年份:
    2013
  • 资助金额:
    $ 166.44万
  • 项目类别:
Factors determining placebo response in drug-resistant focal epilepsy
决定耐药局灶性癫痫安慰剂反应的因素
  • 批准号:
    8583010
  • 财政年份:
    2013
  • 资助金额:
    $ 166.44万
  • 项目类别:
From Cell to Society: A New Method to Characterize Cardiac Autonomic Control
从细胞到社会:表征心脏自主控制的新方法
  • 批准号:
    7503516
  • 财政年份:
    2007
  • 资助金额:
    $ 166.44万
  • 项目类别:
From Cell to Society: A New Method to Characterize Cardiac Autonomic Control
从细胞到社会:表征心脏自主控制的新方法
  • 批准号:
    7846879
  • 财政年份:
    2007
  • 资助金额:
    $ 166.44万
  • 项目类别:
From Cell to Society: A New Method to Characterize Cardiac Autonomic Control
从细胞到社会:表征心脏自主控制的新方法
  • 批准号:
    7364111
  • 财政年份:
    2007
  • 资助金额:
    $ 166.44万
  • 项目类别:
From Cell to Society: A New Method to Characterize Cardiac Autonomic Control
从细胞到社会:表征心脏自主控制的新方法
  • 批准号:
    7625207
  • 财政年份:
    2007
  • 资助金额:
    $ 166.44万
  • 项目类别:
STATISTICAL METHODS FOR CASE CONTROL SURVIVAL DATA
病例对照生存数据的统计方法
  • 批准号:
    6497997
  • 财政年份:
    2001
  • 资助金额:
    $ 166.44万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了